BEIJING, March 30 -- China is soliciting public review of a set of new rules on stem-cell research.
According to a document published by the National Health and Family Planning Commission and China Food and Drug Administration, stem-cell clinical trials refer to transplantation of stem-cells for the purpose of disease prevention or research.
The document proposes that all clinical records of stem-cell providers and subjects should be kept for at lease 30 years.
Subjects should be observed after clinical trials to assess long-term safety and effectiveness of the research, said the document.
The document also proposed that stem-cell researchers should help subjects understand the goal of research as well as its risks. It also said subjects should be insured and research should stop once adverse reactions emerge.
J-11 fighters in air exercise
Beauties dancing on the rings
Attendants-to-be join Mr. & Miss Campus Contest
Beijing's toughest anti-smoking law takes effect
Family lives in cave for about 50 years in SW China
PLA soldiers operating vehicle-mounted guns in drill
Blind carpenter in E China's Jiangxi
China hosts overseas disaster relief exercise for the first time
20 pairs of twins who will become flight attendants in Sichuan
Obama is sowing discontent in S.China Sea
Rescuers work through night to reach cruise ship survivors
Driving through limbo
Facing down MERSDay|Week
